Table 3. . Clinical studies with COBRA-PzF.

Study	Publication year	Study participants	Follow-up duration	Study design	End point findings	Ref.
Maillard et al.	2017	100 patients (38% with ACS); 151 lesions	1 year	Single-center study	Primary end point: target vessel failure 12%, including 2% mortality, 5% periprocedural MI and 5% target lesion revascularization	[35]
Cutlip et al.	2017	296 patients (31% with ACS); 300 lesions	9 months	Multi-center study	Primary end point: target vessel failure 11.5%, including 0.3% cardiac death, 7.0% MI (1% spontaneous MI), 5.9% target vessel revascularization Secondary end point: angiographic in-stent late lumen loss 0.84 ± 0.48 mm	[40]
Maillard et al.	2020	940 patients (47% with ACS; 62% with high bleeding risk); 1229 lesions	1 year	Multi-center study	Primary end point: Major adverse cardiac event rate of 9.0%, including 3.7% cardiac death, 4.8% MI, 4.3% target lesion revascularization Secondary end point: definite stent thrombosis in 0.7%	[41]
Maillard et al.	2020	77 patients with high bleeding risk (18.2% with ACS); 120 lesions	1 year	Single-center study	Primary end point: treatment with clopidogrel for 1 month, followed by aspirin monotherapy did not result in stent thrombosis Secondary end point: major adverse cardiac events rate of 3.8%, including 0% cardiac death, 0% MI, 3.8% target lesion revascularization	[42]

ACS: Acute coronary syndrome; MI: Myocardial infarction.